• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

静脉推注后的时变表观分布容积和药物半衰期

Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections.

作者信息

Wesolowski Carl A, Wesolowski Michal J, Babyn Paul S, Wanasundara Surajith N

机构信息

Department of Medical Imaging, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.

Department of Radiology, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.

出版信息

PLoS One. 2016 Jul 12;11(7):e0158798. doi: 10.1371/journal.pone.0158798. eCollection 2016.

DOI:10.1371/journal.pone.0158798
PMID:27403663
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4942076/
Abstract

We present a model that generalizes the apparent volume of distribution and half-life as functions of time following intravenous bolus injection. This generalized model defines a time varying apparent volume of drug distribution. The half-lives of drug remaining in the body vary in time and become longer as time elapses, eventually converging to the terminal half-life. Two example fit models were substituted into the general model: biexponential models from the least relative concentration error, and gamma variate models using adaptive regularization for least relative error of clearance. Using adult population parameters from 41 studies of the renal glomerular filtration marker 169Yb-DTPA, simulations of extracellular fluid volumes of 5, 10, 15 and 20 litres and plasma clearances of 40 and 100 ml/min were obtained. Of these models, the adaptively obtained gamma variate models had longer times to 95% of terminal volume and longer half-lives.

摘要

我们提出了一个模型,该模型将静脉推注后作为时间函数的表观分布容积和半衰期进行了推广。这个广义模型定义了一个随时间变化的药物分布表观容积。体内剩余药物的半衰期随时间变化,并且随着时间的推移会变长,最终收敛到终末半衰期。将两个示例拟合模型代入到通用模型中:来自最小相对浓度误差的双指数模型,以及使用自适应正则化以实现清除率最小相对误差的伽马变量模型。利用来自41项关于肾小球滤过标志物169Yb - DTPA研究的成年人群参数,获得了细胞外液体积分别为5、10、15和20升以及血浆清除率分别为40和100 ml/min的模拟结果。在这些模型中,通过自适应获得的伽马变量模型达到终末容积95%的时间更长,半衰期也更长。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/0364495b84b0/pone.0158798.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/6c82f6102939/pone.0158798.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/a13e8f09a126/pone.0158798.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/3155f72ebf67/pone.0158798.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/0364495b84b0/pone.0158798.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/6c82f6102939/pone.0158798.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/a13e8f09a126/pone.0158798.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/3155f72ebf67/pone.0158798.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ef15/4942076/0364495b84b0/pone.0158798.g004.jpg

相似文献

1
Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections.静脉推注后的时变表观分布容积和药物半衰期
PLoS One. 2016 Jul 12;11(7):e0158798. doi: 10.1371/journal.pone.0158798. eCollection 2016.
2
Clearance kinetics of solutes used to measure glomerular filtration rate.用于测量肾小球滤过率的溶质清除动力学。
Nucl Med Commun. 1999 Nov;20(11):1047-54. doi: 10.1097/00006231-199911000-00010.
3
Comparative microvascular exchange kinetics of [(77)Br]bromide and (99m)Tc-DTPA in humans.[(77)溴]溴化物与(99m)锝-二乙三胺五乙酸在人体中的微血管交换动力学比较
Eur J Nucl Med Mol Imaging. 2002 May;29(5):655-62. doi: 10.1007/s00259-001-0746-5. Epub 2002 Mar 6.
4
Estimation of extracellular fluid volume from plasma clearance on technetium-99m DTPA by a single-injection, two-sample method.通过单次注射、双样本法,利用锝-99m二乙三胺五乙酸血浆清除率估算细胞外液量。
J Nucl Med. 1988 Feb;29(2):255-8.
5
Tikhonov adaptively regularized gamma variate fitting to assess plasma clearance of inert renal markers.使用 Tikhonov 自适应正则化伽马变量拟合评估惰性肾标志物的血浆清除率。
J Pharmacokinet Pharmacodyn. 2010 Oct;37(5):435-74. doi: 10.1007/s10928-010-9167-z. Epub 2010 Sep 24.
6
Single-sample 99mTc-diethylenetriamine penta-acetate plasma clearance in advanced renal failure by the mean sojourn time approach.采用平均滞留时间法测定晚期肾衰竭患者单样本99mTc-二乙三胺五乙酸血浆清除率
Nucl Med Commun. 2009 Mar;30(3):202-5. doi: 10.1097/MNM.0b013e328315e0c6.
7
The technetium-99m-DTPA renal uptake-plasma volume product: a quantitative estimation of glomerular filtration rate.锝-99m-二乙三胺五乙酸肾摄取-血浆容量乘积:肾小球滤过率的定量评估
J Nucl Med. 1992 Sep;33(9):1712-6.
8
Radionuclide method for evaluating the performance of hemodialysis in vivo.体内评估血液透析性能的放射性核素方法。
Kidney Int. 2005 Feb;67(2):721-31. doi: 10.1111/j.1523-1755.2005.67133.x.
9
Chromium-51-EDTA clearance in adults with a single-plasma sample.单份血浆样本检测成人的铬-51-乙二胺四乙酸清除率
J Nucl Med. 1998 Dec;39(12):2131-7.
10
Simultaneous measurement of extracellular fluid distribution and renal function with a single injection of 99mTc DTPA.单次注射99mTc DTPA同时测量细胞外液分布和肾功能。
Nephrol Dial Transplant. 1995 Oct;10(10):1829-33.

引用本文的文献

1
The Importance of Murine Models in Determining In Vivo Pharmacokinetics, Safety, and Efficacy in Antimalarial Drug Discovery.小鼠模型在抗疟药物发现中确定体内药代动力学、安全性和疗效方面的重要性。
Pharmaceuticals (Basel). 2025 Mar 18;18(3):424. doi: 10.3390/ph18030424.
2
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars.美国食品药品监督管理局的新指南“普遍接受的科学知识”(GASK):加速生物类似药批准的一个契机。
Pharmaceuticals (Basel). 2023 Oct 25;16(11):1517. doi: 10.3390/ph16111517.
3
Scientific Rationale for Waiving Clinical Efficacy Testing of Biosimilars.

本文引用的文献

1
Accurate and precise plasma clearance measurement using four 99mTc-DTPA plasma samples over 4 h.在4小时内使用四个99mTc-DTPA血浆样本进行准确且精确的血浆清除率测量。
Nucl Med Commun. 2016 Jan;37(1):79-86. doi: 10.1097/MNM.0000000000000405.
2
Volume of Distribution in Drug Design.药物设计中的分布容积。
J Med Chem. 2015 Aug 13;58(15):5691-8. doi: 10.1021/acs.jmedchem.5b00201. Epub 2015 Apr 1.
3
The early plasma concentration of 51Cr-EDTA in patients with cirrhosis and ascites: a comparison of three models.肝硬化腹水患者51Cr-乙二胺四乙酸的早期血浆浓度:三种模型的比较
生物类似药豁免临床疗效测试的科学依据
Drug Des Devel Ther. 2022 Aug 24;16:2803-2815. doi: 10.2147/DDDT.S378813. eCollection 2022.
4
Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review.肥胖患者的化疗与抗癌药物调整:一项叙述性综述
Curr Med Chem. 2023;30(9):1003-1028. doi: 10.2174/0929867329666220806140204.
5
Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.普兰替啶,一种新型的每日一次口服非肽类 SST2 受体激动剂,可抑制健康志愿者的 GH 和 IGF-1。
Pituitary. 2022 Apr;25(2):328-339. doi: 10.1007/s11102-021-01201-z. Epub 2022 Jan 9.
6
A series acceleration algorithm for the gamma-Pareto (type I) convolution and related functions of interest for pharmacokinetics.一个用于伽马-Pareto(I 型)卷积和药代动力学相关感兴趣函数的系列加速算法。
J Pharmacokinet Pharmacodyn. 2022 Apr;49(2):191-208. doi: 10.1007/s10928-021-09779-4. Epub 2021 Oct 24.
7
Computational approach towards the design of artemisinin-thymoquinone hybrids against main protease of SARS-COV-2.针对抗SARS-CoV-2主要蛋白酶的青蒿素-百里醌杂合物设计的计算方法。
Futur J Pharm Sci. 2021;7(1):185. doi: 10.1186/s43094-021-00334-z. Epub 2021 Sep 6.
8
Comparison of the gamma-Pareto convolution with conventional methods of characterising metformin pharmacokinetics in dogs.比较伽马-帕累托卷积与常规方法在狗体内表征二甲双胍药代动力学的特点。
J Pharmacokinet Pharmacodyn. 2020 Feb;47(1):19-45. doi: 10.1007/s10928-019-09666-z. Epub 2019 Dec 21.
9
Comparison of Performance of Improved Serum Estimators of Glomerular Filtration Rate (GFR) to Tc-DTPA GFR Methods in Patients with Hepatic Cirrhosis.肝硬化患者中改良血清肾小球滤过率(GFR)估算值与Tc-DTPA GFR测定方法的性能比较
J Nucl Med Technol. 2017 Mar;45(1):42-49. doi: 10.2967/jnmt.116.180851. Epub 2017 Feb 2.
10
A gamma-distribution convolution model of Tc-MIBI thyroid time-activity curves.Tc-MIBI 甲状腺时间-活性曲线的伽马分布卷积模型。
EJNMMI Phys. 2016 Dec;3(1):31. doi: 10.1186/s40658-016-0166-z. Epub 2016 Dec 16.
Nucl Med Commun. 2015 Apr;36(4):392-7. doi: 10.1097/MNM.0000000000000255.
4
Validation of Tikhonov adaptively regularized gamma variate fitting with 24-h plasma clearance in cirrhotic patients with ascites.腹水肝硬化患者 24 小时血浆清除率的 Tikhonov 自适应正则化伽马变量拟合验证。
Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2247-56. doi: 10.1007/s00259-011-1887-9. Epub 2011 Sep 1.
5
Tikhonov adaptively regularized gamma variate fitting to assess plasma clearance of inert renal markers.使用 Tikhonov 自适应正则化伽马变量拟合评估惰性肾标志物的血浆清除率。
J Pharmacokinet Pharmacodyn. 2010 Oct;37(5):435-74. doi: 10.1007/s10928-010-9167-z. Epub 2010 Sep 24.
6
The effect of improved modelling of plasma clearance in paediatric patients with expanded body spaces on estimation of the glomerular filtration rate.改良的儿童扩张腔室患者血浆清除率模型对肾小球滤过率估算的影响。
Physiol Meas. 2010 Feb;31(2):183-92. doi: 10.1088/0967-3334/31/2/005. Epub 2009 Dec 16.
7
The connection between the steady state (Vss) and terminal (Vbeta) volumes of distribution in linear pharmacokinetics and the general proof that Vbeta >/= Vss.线性药代动力学中稳态分布容积(Vss)与终末分布容积(Vβ)之间的关系以及Vβ≥Vss的一般证明。
J Pharm Sci. 2007 Jun;96(6):1638-52. doi: 10.1002/jps.20804.
8
Volumes of distribution.分布容积
J Vet Pharmacol Ther. 2004 Dec;27(6):441-53. doi: 10.1111/j.1365-2885.2004.00602.x.
9
Plasma clearance.血浆清除率
J Vet Pharmacol Ther. 2004 Dec;27(6):415-25. doi: 10.1111/j.1365-2885.2004.00605.x.
10
Determination of inulin clearance by bolus intravenous injection in healthy subjects and ascitic patients: equivalence of systemic and renal clearances as glomerular filtration markers.通过静脉推注法测定健康受试者和腹水患者的菊粉清除率:作为肾小球滤过标志物的全身清除率和肾清除率的等效性。
Br J Clin Pharmacol. 1998 Dec;46(6):605-9. doi: 10.1046/j.1365-2125.1998.00824.x.